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ABSTRACT 
A series of pyrimidoquinazoline are prepared via the reaction of ethyl 2,2-dicyano-1-arylvinylcarbamate 
derivatives 1a-b with methyl 2-aminobenzoate, 1-(2-aminophenyl)ethanone and 2-aminobenzonitrile. The reactivity of 
compounds 1a-b toward 3-amino-4,6-diphénylnicotinonitrile are studied. The structures of the synthesized compounds are 
elucidated by X-ray diffraction, IR spectroscopy and nuclear magnetic resonance.  
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INTRODUCTION 
Pyrimidoquinazoline compounds have fascinated researchers for a long time; they are used in a wide range of 
applications in pharmaceutical chemistry. Multiple methods of preparation of these compounds have been developed [1-
5], they’ve come up with the result that pyrimidoquinazoline derivatives exhibit anti-inflammatory [6, 7], anti-cancer [7] and 
antioxidant activities [8]. 
In search of an efficient method of preparation of pyrimidoquinazoline compounds, and following our work on synthesis of 
polyheterocyclic systems which contain pyrimidinone moiety [9-11], we report here the synthesis of some new 
pyrimido[1,6-a]quinazoline-4-carbonitrile and tetrahydropyrimidine-5-carbonitrile derivatives.  
RESULTS AND DISCUSSION 
 The ethyl 2,2-dicyano-1- arylvinylcarbamate derivatives 1a-b, used in this study, are prepared by condensation of 
malononitrile with ethyl N-(ethoxycaronyl)imidates  by a previously reported method [12]. 
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Scheme 1: Synthetic route to ethyl 2,2-dicyano-1-arylvinylcarbamate 
Condensation of substrates 1a-b (which contain  functionality (CN and CO)) with methyl 2-aminobenzoate or 1-(2-
aminophenyl) ethanone in chlorobenzene for 4h give tricyclic 1H-pyrimido[1,6-a]quinazoline-4-carbonitrile derivatives 2a-b 
and 3a-b. The first step of the mechanism involves the condensation of the NH2 group with ester and cyano groups of 1a-
b, in which the nonisolable intermediates 2’a-b and 3’a-b are obtained first, then, followed by an internal nucleophilic 
attack by the NH2 group of the pyrimidinone ring on the ester or ketone group to yield 2a-b and 3a-b (Scheme 2). 
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Scheme 2: Synthetic route to pyrimidoquinazoline 
In the 
1
HNMR spectra (2a-b) the most significant information is the disappearance of the methoxy group’s singlet of 
the starting reagent methyl 2-aminobenzoate. This proves that the amino group attacks the ester function. In the IR 
spectra (3a-b), the absorption band at around 3200-3400 cm
-1
 corresponding to amino group, is not observed. The 
1
HNMR spectra shows the presence of methyl group from the cycloadduct 3a at δ 3.02 (s, 3H, CH3-C=N-) and tow methyl 
groups from the cycloadduct 3b at δ 2.42(s, 3H, CH3-C6H4-) and δ 3.02 (s, 3H, CH3-C=N-). 
Moreover, heating compounds 1a-b and 2-aminobenzonitrile in chlorobenzene leads to the formation of the 
corresponding pyrimidinone 4’a-b or pyrimidoquinazoline derivatives 4a-b (Scheme 2). Regarding the last reaction 
(formation of 2a-b and 3a-b) we can hypothesize the formation of compounds 4a-b. Yet, spectral data does not show 
exactly which product is formed 4a-b or 4’a-b.  
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Scheme 3: Synthetic route to 6-amino-pyrimidoquinazoline 
In order to know which specific product is formed, an X-ray crystallographic study of the compound 4a was carried out 
(Figure 1). This study, showed only the formation of compounds 4a-b and not 4’a-b.   
 
 
Figure 1: X-ray crystal analysis of the compound 4a 
 
 
X-ray data diffraction of the compound 4a: C21H18N6O2, M = 386.41 g.mol
-1
, monoclinic, space group P21/c, a = 
16.077 (9), b = 16.228 (9), c = 7.484 (4) Å, β = 91.296 (10) °, V = 1951.8(19) Å
3
, Z = 4, 1563 reflections with I>2σ(I) used 
for the refinement of the crystal structure. The final discrepancy factors R1 and wR2 were found to be 0.058 and 0.137. 
Furthermore, the reaction of 1a-b with 3-amino-4,6-diphénylnicotinonitrile afforded 1,2,3,4-tetrahydropyrimidine -
5-carbonitrile derivatives 5a-b and not pyrimidoquinazoline 5’a-b structures (Scheme 4). 
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 The structures of compounds 5a-b are congruent with their spectral data. The decoupled 
13
CNMR spectra show 
two signals at δ 115-118. This is due to the carbon atom in the two cyano groups. Besides, 
1
HNMR spectra indicate two 
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singlets at δ 12.20-13.20 for the two NH groups. To confirm the suggested structures, the compound 5a was analyzed by 
X-ray diffraction. 
X-ray results indicate the formation of the compound 5a and not 5’a (Figure 2).  
 
Figure 2: X-ray crystal analysis of the compound 5a 
X-ray data diffraction of the compound 5a: C29H18N6O, M = 466.49 g.mol
-1
, monoclinic, space group P21/n, a = 
10.635 (2), b = 25.782 (5), c = 17.906 (3) Å, β = 107.028 (3) °, V = 4694.8 (2) Å
3
, Z = 8, 2782 reflections with I>2σ(I) used 
for the refinement of the crystal structure. The final discrepancy factors R1 and wR2 were found to be 0.073 and 0.167. 
We suggest the following mechanism: first, the formation of nonisolable intermediate by condensation of the NH2 group 
with cyano group of 1a-b followed by an internal nucleophilic attack by the NH leading to our product (Scheme 5).  
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CONCLUSION 
 In conclusion, in this work we have reported the synthesis of some new pyrimidoquinazoline and pyrimidine 
derivatives.  Results demonstrate that 2-aminobenzonitrile and 3-amino-4,6-diphénylnicotinonitrile react differently to the 
compound 1a-b even though they have the same functions. 
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EXPERIMENTAL 
  Melting points are recorded in degrees Celsius on a Kofler apparatus. All reactions were followed by TLC (E. Merck 
Kieselgel 60 F-254), with UV detection at 254 nm.  The IR spectra were recorded in the solid state as KBr discs on a 
Perkin-Elmer PARAGON 1000 FT-IR spectrometer. 
1
H and 
13
C NMR were determined in solution in DMSO-d6 with an AC 
Bruker spectrometer at 300 MHz using TMS as an internal standard. The mass spectra were recorded on an ion trap 
mass spectrometer (Finnigan LCQ Deca XP Max) using electrospray as an ionization source. The purity of all compounds 
was determined by LC-PDA-MS methods and was found to be in the range between 96-99%.  
A suitable crystal was carefully selected under a polarizing microscope and mounted at the end of a thin glass 
fiber. Crystal structures determination were performed using a BRUKER SMART APEX CCD diffractometer which uses 
graphite monochromatized MoK radiation (λ = 0.71073 Å). Unit cell parameters, optimized by least-squares refinement 
were calculated and refined using indexation of collected intensities. Structures were solved by direct methods using 
SHELXS-97 [13] and refined by full-matrix least-squares procedures using the SHELXL-97 program [14]. 
GENERAL EXPERIMENTAL PROCEDURE 
      To a magnetically stirred solution of the ethyl 2,2-dicyanolvinylcarbamate derivatives 1a-b (0.255 g: 1 mmol) in 
chlorobenzene (10 mL), the appropriate amines (1.2 mmol) were added and the reaction mixture stirred for 2~4 h at 110 
°C. The progress of the reaction was monitored by TLC (mobile phase, ethyl acetate: dichloromethane; 60/40;v/v). The 
resulting mixture was allowed to cool at room temperature. The precipitate formed was isolated by filtration and washed 
with diethyl ether to obtain the pure product. 
Spectral Data of New Compounds 
1,6-dioxo-3-phenyl-5,6-dihydro-1H-pyrimido[1,6-a]quinazoline-4-carbonitrile (2a). Rdt (63%), C18H10N4O2, 
M=314g.mol
-1
, mp> 300°C; IR (KBr) ν:3204 (NH), 2236 (CN), 1756 (C=O), 1688 (C=O),  1624 (C=N) cm
−1
;        
1
H-NMR: 
(DMSO-d6): δ = 7.49–8.20 (m,10H, Ar-H + NH); 
13
C-NMR (DMSO-d6): δ = 59.1 (C4), 115.5 (CN), 148.0 (C=C-N), 157.1 
(C1), 159.0 (C6), 169.5 (C3), 120.9-147.8(Carom); MS-(+)ESI: m/z (%):315 ([M+H]
+
, 100).        
1,6-dioxo -3-p-tolyl-5,6-dihydro-1H-pyrimido[1,6-a]quinazoline-4-carbonitrile (2b). Rdt (65%), C19H12N4O2, 
M=328g.mol
-1
, mp= 275°C; IR (KBr) ν:3225 (NH), 2218 (CN), 1748 (C=O), 1685 (C=O), 1619 (C=N)  cm
−1
;  
1
H-NMR: 
(DMSO-d6): δ = 2.1(s, 3H, CH3), 7.36–8.08 (m,9H, Ar-H + NH); 
13
C-NMR (DMSO-d6): δ = 20.8 ( CH3), 87.1 (C4), 116.6 
(CN), 149.8 (C=C-N), 157.8 (C1), 158.8 (C6), 167.5 (C3), 120.3-147.4(Carom); MS-(+)ESI: m/z (%):329([M+H]
+
,100).                                                                                                                                                
 6-methyl-1-oxo-3-phenyl-1H-pyrimido[1,6-a]quinazoline-4-carbonitrile (3a). Rdt (57%), C19H12N4O, M=312g.mol
-1
, 
mp= 256°C; IR (KBr) ν: 2224 (CN), 1720 (C=O),  1595 (C=N) cm
−1
;  
1
H-NMR: (DMSO-d6): δ = 3.02 (s, 3H), 7.26–8.39 
(m,9H, Ar-H); 
13
C-NMR (DMSO-d6): δ = 23.9 (CH3), 84.3 (C4), 116.6 (CN), 156.7 (C=C-N), 169.6 (C1), 175.0 (C3), 120.1-
136.3(Carom); MS-(+)ESI: m/z (%):313 ([M+H]
+
, 100).                                             
6-methyl-1-oxo-3-p-tolyl-1H-pyrimido[1,6-a]quinazoline-4-carbonitrile (3b). Rdt (59%), C20H14N4O, M=326g.mol
-1
, 
mp= 257°C; IR (KBr) ν: 2222 (CN), 1705 (C=O),  1595 (C=N) cm
−1
;  
1
H-NMR: (DMSO-d6): δ = 2.42 (s, 3H), 3.02 (s, 3H, 
CH3), 7.32–8.42 (m,8H, Ar-H); 
13
C-NMR (DMSO-d6): δ = 21.5 (CH3), 23.8 (CH3), 86.2 (C4), 116.7 (CN), 156.8 (C=C-N), 
169.5 (C1), 174.8 (C3), 120.4-142.6(Carom); MS-(+)ESI: m/z (%):327 ([M+H]
+
, 100).  
6-amino-1-oxo-3-phenyl-1H-pyrimido[1,6-a]quinazoline-4-carbonitrile (4a). Rdt (61%), C18H11N5O, M=313g.mol
-1
, 
mp> 300°C; IR (KBr) ν: 3420–3332 (NH2), 2209 (CN), 1713 (C=O) cm
−1
;
 1
HNMR(DMSOd6):δ=7.5-9.2(m,9H,Harom); 
9.3(s,2H,NH2).
 13
CNMR(DMSO-d6): 81.6 (C4); 117.3(CN); Carom,120.8-136.4 ; 152.6 (C1); 157.7 (C6) ; 160.1(C3); 169.3 
(C5); MS-(+)ESI: m/z (%):314 ([M+H]
+
, 100).                                                                       
6-amino-1-oxo-3-p-tolyl-1H-pyrimido[1,6-a]quinazoline-4-carbonitrile (4b). Rdt (74%), C19H13N5O, M=327g.mol
-1
, mp> 
300°C; IR (KBr) ν: 3440–3312 (NH2), 2211 (CN), 1679 (C=O) cm
−1
;  
1
HNMR(DMSOd6):δ= 2.41 (s, 3H, CH3), 7.3–9.2 
(m,8H, Harom), 9.3 (s, 2H, NH2).
13
CNMR(DMSO-d6): 21.5(CH3),  81.8 (C4); 118.0 (CN); Carom,121.3-141.9 ; 153.1 (C1);  
158.2(C6); 160.5 (C3); 169.5 (C5);  MS-(+)ESI: m/z (%):328 ([M+H]
+
, 100).      
(Z)4-(3-cyano-4,6-diphenylpyridin-2-ylimino)-2-oxo-6-phenyl-1,2,3,4-tetrahydropyrimidine-5-carbonitrile (5a): Rdt 
(58%), C29H18N6O,  M=466g.mol
-1
, mp> 300°C ; IR (KBr) ν: 3421 (NH), 2228 (CN), 1702 (C=O);  
1
HNMR (DMSOd6):δ= 
7.4-7.80(m,16H,Harom); 12.28(s,1H,NH); 13.20(s,1H,NH);
 13
CNMR(DMSO-d6): 87.5(C5); 115.35 and 116.48 (CN); 
Carom,128.05-137.75; 148.51(C2);  152.39(C6); 161.55(C4) ; MS-(+)ESI: m/z (%):467 ([M+H]
+
, 100).          
(Z)-4-(3-cyano-4,6-diphenylpyridin-2-ylimino)-2-oxo-6-p-tolyl-1,2,3,4-tetrahydropyrimidine-5-carbonitrile (5b): Rdt = 
(53%); C30H20N6O,  M=480g.mol
-1
, mp> 300°C; IR (KBr) :ν =3467(NH), 2229 (CN), 1693  (C=O); 
1
HNMR (DMSOd6):δ=2. 
5( s, 3H) , 7.5-8.25(mu ,15Harom), 12.34(s,1H,NH); 13.15(s,1H,NH);
 13
CNMR(DMSO-d6): 20.0 (CH3); 87.83 (C5); 116.11 
and 117.93 (CN), 128.41-137.68 (Carom); 149.32(C2); 152.15(C6); 158.35(C4);   MS-(+)ESI: m/z (%):481 ([M+H]
+
, 100). 
ACKNOWLEDGMENTS 
Thanks are due to the Ministry of Higher Education and Scientific Research and Technology in Tunisia and Sfax 
University for financial support. 
 
 
ISSN 2321-807X 
1439 | P a g e                                                         M a r c h  0 1 ,  2 0 1 4  
REFERENCES 
[1] E. B. Skibo, X. Huang, R. Martinez, R. H. Lemus, W. A. Craigo, R. T. Dorr, J. Med. Chem.45 (2002) 5543.      
[2] E. B. Skibo, J. H. Gilchrist, J. Org. Chem.  53 (1988) 4209.                                                                                 
[3] S. Nag, A. Mishra, S. Batra, Tetrahedron 64 (2008) 10162. 
[4] W. J. Li, S. Liu, P. He, M.W. Ding, Tetrahedron 66 (2010) 8151.                                                                         
[5] T. Saito, K. Tsuda, Tetrahedron Letters 37 (1996) 9071. 
[6] A.A. Abu-Hashem, M.A. Gouda, F.A. Badria, European Journal of Medicinal Chemistry 45 (2010) 1976. 
[7] P. Mani Chandrika, T. Yakaiah, A. Raghu Ram Rao, B. Narsaiah, N. Chakra Reddy, V. Sridhar, J. V. Rao, European 
Journal of Medicinal Chemistry, 43 (2008)846. 
[8] A.B.A. El-Gazzar, M.M. Youssef, A.M.S. Youssef, A.A. Abu-Hashem, F.A. Badria, European Journal of      Medicinal 
Chemistry, 44 (2009) 609. 
[9] E. Najahi, J. Sudor, F. Chabchoub, F. Nepveu, F. Zribi,  R. Duval, Molecules, 15 (2010) 8841.                       
[10] E. Najahi, J. Sudor, F. Nepveu, F. Zribi, R. Duval, F. Chabchoub, Heterocyclic Letters, 1 (2011)  9.             
[11] F. Zribi, M. Trabelsi, M. Salem, J. Tun. Chem. Soc. 5 (2003) 193.                                                                  
[12] F. Zribi, A. Rekik, F. Chabchoub, M. Trabelsi, M. Salem, J. Tun. Chem. Soc. 4 (2001) 965. 
[13] Sheldrick, G.M. SHELXS-97 Program for the Solution of Crystal Structures, University of Göttingen, Germany, 1997. 
[14] Sheldrick, G.M. SHELXL-97 Program for Crystal Structure Refinement, University of Göttingen, Germany, 1997. 
 
 
